LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Inicio・Lista de Acciones・AnaptysBio Inc

AnaptysBio Inc

Cerrado

SectorSanidad

51.39 1.86

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

49.8

Máximo

52.53

Métricas clave
By Trading Economics
Ingresos	-102M -53M
Ventas	-83M 26M
BPA	-1.843
Margen de beneficios	-206.934
Empleados	104
EBITDA	-102M -34M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+43.93% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-430M 1.5B
Apertura anterior	49.53
Cierre anterior	51.39

Noticias sobre sentimiento de mercado

By Acuity

93%

319 / 344 Clasificación en Healthcare

AnaptysBio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 jun 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 jun 2026, 15:41 UTC

Principales Movimientos del Mercado

American Battery Shares Jump on Energy Department Victory

8 jun 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 jun 2026, 23:37 UTC

Charlas de Mercado

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 jun 2026, 23:25 UTC

Charlas de Mercado

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 jun 2026, 23:25 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 jun 2026, 21:57 UTC

Adquisiciones, fusiones, absorciones

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 jun 2026, 21:56 UTC

Adquisiciones, fusiones, absorciones

Salesforce Agrees to Buy m3ter

8 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

8 jun 2026, 19:22 UTC

Charlas de Mercado

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 jun 2026, 19:01 UTC

Charlas de Mercado

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 jun 2026, 18:52 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

8 jun 2026, 18:52 UTC

Charlas de Mercado

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 jun 2026, 18:17 UTC

Charlas de Mercado

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 jun 2026, 17:32 UTC

Charlas de Mercado

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 jun 2026, 17:29 UTC

Charlas de Mercado

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 jun 2026, 17:29 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 jun 2026, 16:55 UTC

Adquisiciones, fusiones, absorciones

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 jun 2026, 16:54 UTC

Adquisiciones, fusiones, absorciones

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 jun 2026, 16:40 UTC

Charlas de Mercado

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 jun 2026, 16:31 UTC

Charlas de Mercado

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 jun 2026, 16:27 UTC

Charlas de Mercado

Mexican Inflation Seen Easing in May -- Market Talk

8 jun 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 jun 2026, 16:03 UTC

Adquisiciones, fusiones, absorciones

Orange Bought Stake From Lorca

8 jun 2026, 16:01 UTC

Adquisiciones, fusiones, absorciones

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 jun 2026, 16:01 UTC

Adquisiciones, fusiones, absorciones

Orange Acquires 100% Ownership of MasOrange

8 jun 2026, 15:58 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 jun 2026, 15:58 UTC

Charlas de Mercado

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 jun 2026, 15:55 UTC

Charlas de Mercado

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 jun 2026, 15:41 UTC

Charlas de Mercado

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparación entre iguales

Cambio de precio

AnaptysBio Inc previsión

Precio Objetivo

By TipRanks

43.93% repunte

Estimación a 12 Meses

Media 72.5 USD 43.93%

Máximo 93 USD

Mínimo 50 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AnaptysBio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para AnaptysBio Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

319 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.